tirzepatide weight loss stall Time to plateau with treatment in the SURMOUNT‐1 and SURMOUNT‐4 clinical trials Why Weight Loss Plateaus on

If your gastroenterologist and your prescriber are discussing semaglutide for body weight rather than for glycemic control, the product under discussion is Wegovy, whose labeled purposes include reducing excess body weight and maintaining weight reduction long term in adults with obesity or with overweight plus at least one weight-related comorbid condition

Some patients find that low-dose ondansetron taken 30 minutes before injection significantly reduces nausea without affecting weight loss outcomes

In those situations, families may need help determining whether detox, residential treatment, rehab placement, sober transport, intervention planning, or sober companion support is the appropriate next step

Clinical evidence from the STEP trials demonstrated that semaglutide produced an average 15% body weight loss over 68 weeks when combined with lifestyle changes, compared to 2.6% with placebo

Wegovy (semaglutide injection) is a leading choice in injectable GLP-1 medications for weight loss